Evidence map›Paper›PMID 25278510›Full record

Observational studyJournal of the American Society of Nephrology : JASN2015

High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study.

Nisha Bansal, Amanda Hyre Anderson, Wei Yang, Robert H Christenson, Christopher R deFilippi, Rajat Deo, Daniel L Dries, Alan S Go, Jiang He, John W Kusek and 7 more

Erratum issuedOpen access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 121 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Comparative analysis of plasma BNP and NT-proBNP levels, and NT-proBNP/BNP ratio in patients with chronic kidney disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Cardiac Troponins in Kidney Disease.European cardiology · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Descriptions and Determinants of N-Terminal Pro-B-Type Natriuretic Peptide in Pediatric CKD: The Chronic Kidney Disease in Children (CKiD) Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023
    Article
  19. Article
  20. Brain Natriuretic Peptide Monitoring in CKD: Ready for Prime Time?American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023
    Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

Nisha BansalUniversity of Washington, Seattle, Washington; nbansal@nephrology.washington.edu.
Amanda Hyre AndersonUniversity of Pennsylvania, Philadelphia, Pennsylvania;
Wei YangUniversity of Pennsylvania, Philadelphia, Pennsylvania;
Robert H ChristensonUniversity of Maryland, School of Medicine, Baltimore, Maryland;
Christopher R deFilippiUniversity of Maryland, School of Medicine, Baltimore, Maryland;
Rajat DeoUniversity of Pennsylvania, Philadelphia, Pennsylvania;
Daniel L DriesYale University, New Haven, Connecticut;
Alan S GoKaiser Permanente Northern California, Oakland, California;
Jiang HeTulane University, New Orleans, Louisiana;
John W KusekNational Institutes of Health, Bethesda, Maryland;
James P LashUniversity of Illinois, Chicago, Illinois;
Dominic RajThe George Washington University, Washington, DC;
Sylvia RosasUniversity of Pennsylvania, Philadelphia, Pennsylvania;
Myles WolfNorthwestern University, Feinberg School of Medicine, Chicago, Illinois; and.
Xiaoming ZhangUniversity of Pennsylvania, Philadelphia, Pennsylvania;
Michael G ShlipakUniversity of California, San Francisco, California.
Harold I FeldmanUniversity of Pennsylvania, Philadelphia, Pennsylvania;
University of Pennsylvania · USUniversity of Maryland, Baltimore · USGeorge Washington University · USKaiser Permanente · USNational Institutes of Health · USNorthwestern University · USTulane University · USUniversity of California, San Francisco · USUniversity of Illinois Chicago · USUniversity of Washington · USYale University · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI ONUKWUGHA, EBERECHUKWU · 2002 to 2009
$20.2M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
Limited Competition for the Continuation of the Chronic Renal Insufficiency CohorU01DK061021 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI RAHMAN, MAHBOOB · 2001 to 2025
$17.3M
Prospective Renal Insufficiency Cohort Evaluation:PRICEU01DK060984 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI COHEN, DEBBIE L · 2001 to 2025
$17.0M
Prospective Cohort Study of Chronic Renal InsufficiencyU01DK061028 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, PANDURANGA S · 2001 to 2025
$16.9M
Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Hopkins Clinical CenterU01DK061022 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI APPEL, LAWRENCE JOHN · 2001 to 2025
$15.7M
Proposal for a Chicago-CRIC Clinical CenterU01DK060980 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LASH, JAMES P. · 2001 to 2025
$15.4M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1-TR000003NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1-TR-000424NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1-TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1-TR000439NCRR NIH HHS M01 RR016500NCRR NIH HHS M01 RR-16500NCRR NIH HHS UL1 RR-024131NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR029879NCRR NIH HHS UL1-RR029879NIDDK NIH HHS 1DK066488NIDDK NIH HHS K01 DK092353NIDDK NIH HHS K01-DK092353NIDDK NIH HHS K23 DK088865NIDDK NIH HHS K23-DK088865NIDDK NIH HHS K24 DK002651NIDDK NIH HHS K24-DK02651NIDDK NIH HHS K24 DK093723NIDDK NIH HHS R01 DK066488NIDDK NIH HHS R01 DK072231NIDDK NIH HHS R01 DK081374NIDDK NIH HHS R01 DK103612NIDDK NIH HHS R01 DK139225NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01-DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01-DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01-DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01-DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01-DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01-DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01-DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U01-DK061028NIGMS NIH HHS P30 GM103337NIGMS NIH HHS P30-GM103337
6 · The paper itself

Abstract

High-sensitivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) strongly predict heart failure (HF) in the general population. However, the interpretation of levels of these biomarkers as predictors of HF is uncertain among patients with CKD. Here, we investigated whether hsTnT and NT-proBNP are associated with incident HF among patients with CKD. In a prospective cohort analysis, we studied 3483 people with CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study recruited from June of 2003 to August of 2008 who were free of HF at baseline. We used Cox regression to examine the association of baseline levels of hsTnT and NT-proBNP with incident HF after adjustment for demographic factors, traditional cardiovascular risk factors, markers of kidney disease, pertinent medication use, and mineral metabolism markers. At baseline, hsTnT levels ranged from ≤5.0 to 738.7 pg/ml, and NT-proBNP levels ranged from ≤5 to 35,000 pg/ml. Compared with those who had undetectable hsTnT, participants in the highest quartile (>26.5 pg/ml) had a significantly higher rate of HF (hazard ratio, 4.77; 95% confidence interval, 2.49 to 9.14). Similarly, compared with those in the lowest NT-proBNP quintile (<47.6 pg/ml), participants in the highest quintile (>433.0 pg/ml) experienced a substantially higher rate of HF (hazard ratio, 9.57; 95% confidence interval, 4.40 to 20.83) [corrected]. In conclusion, hsTnT and NT-proBNP were strongly associated with incident HF among a diverse cohort of individuals with mild to severe CKD. Elevations in these biomarkers may indicate subclinical changes in volume and myocardial stress that subsequently contribute to clinical HF.

Indexed as

AdultAgedBiomarkersFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsRenal Insufficiency, ChronicTroponin TBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Troponin Tcardiovascular diseaseheart failurekidney disease

Identifiers

PMID25278510
PMCPMC4378105
OpenAlexW2129285632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.